AI Agents Reshape Drug Discovery: Experts Discuss Isomorphic's Prospects
xhluca · x · 2026-08-06
Regarding AI applications in pharmaceuticals, an expert points out that the primary "users" will shift towards AI agents that execute the complete discovery loop, with humans only handling end results like clinical trials. The expert suggests highly focused companies like Isomorphic are more likely to secure big pharma contracts, while anticipating similar discovery tools emerging for broader molecular engineering.
More from AGI Musings
- USV's Rebecca Kaden: AI Remains Dramatically Underhyped, Public Thinking is Our Alpha — rebeccakaden · 2026-08-06
- Google to Take Huge Equity in AI Labs in Exchange for Compute Power — generativist · 2026-08-06
- The Hard Truth of AI Drug Discovery: Everyone Wants Discovery, Nobody Makes Drugs — Ronangmi · 2026-08-06
- Yi Ma Reaffirms Closed-Loop Feedback: End-to-End Will Return to Closed-Loop Learning — YiMaTweets · 2026-08-06
- Revisiting George Box: Automating the Scientific Loop as AI's Holy Grail — dustinvtran · 2026-08-06
- David Bau: Core Challenge of AI Era is Ensuring Human Agency — davidbau · 2026-08-06